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Objective: The prevalence of diabetes in sub-Saharan Africa is rising, but its relationship to depression is
not well-characterized. This report describes depressive symptom prevalence and associations with
adherence and outcomes among patients with diabetes in a rural, resource-constrained setting.
Methods: In the Webuye, Kenya diabetes clinic, we conducted a chart review, analyzing data including
medication adherence, hemoglobin A1c (HbA1c), clinic attendance, and PHQ-2 depression screening
results.
Results: Among 253 patients, 20.9% screened positive for depression. Prevalence in females was higher
than in males; 27% vs 15% (p ¼ 0.023). Glycemic control trends were better in those screening negative;
at 24 months post-enrollment mean HbA1c was 7.5 for those screening negative and 9.5 for those
screening positive (p ¼ 0.0025). There was a nonsigniﬁcant (p ¼ 0.269) trend toward loss to follow-up
among those screening positive.
Conclusions: These ﬁndings suggest that depression is common among people with diabetes in rural
western Kenya, which may profoundly impact diabetes control and treatment adherence.
Ó 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Keywords:
Diabetes
Depression
Resource-constrained
Kenya
Sub-Saharan Africa

Introduction
Depression and diabetes mellitus are two chronic disease states
that have a profoundly negative impact on quality of life and overall
life expectancy [1]. They frequently co-occur, and relationships
between both conditions are bidirectional [2]. Some data suggest
that the burden and emotional impact of managing a chronic disease like diabetes may lead to development of mental health
problems such as depression [3]. Conversely, people with depression may develop behavioral factors that lead to an overall lack of
self-care, thereby increasing the risk of developing diabetes [4].
There is more than a threefold increase in the prevalence of
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depression in people with type 1 diabetes, and nearly a two fold
increase in people with type 2 diabetes. However, there is very
limited data on the prevalence of comorbid depression and diabetes
in sub-Saharan Africa [5].
Both hypotheses present serious implications in the management of these comorbid disease states. If diabetes is caused or
exacerbated by depression, then proper management of diabetes
cannot exist without addressing depressive symptoms. Patients
with diabetes experiencing signiﬁcant depressive symptoms are
less likely to engage in diet and exercise recommendations than are
those without depressive symptoms, and have lower medication
adherence than non-depressed counterparts [6]. Comorbid
depression profoundly impacts diabetes self-management and
treatment adherence, and is associated with signiﬁcant risk of
complications including stroke and myocardial infarction. Overall,
comorbid depression in individuals with diabetes is associated with
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a 1.5-fold increase in mortality risk as compared with those without
depression [7].
As such, co-management of diabetes and depression is critical;
in high income countries programs have been established to
co-manage depression and diabetes, but such programs are
virtually nonexistent in sub-Saharan Africa (SSA) [8]. Globally,
mental illnesses such as depression have become an increasingly
prevalent component of the overall burden of disease [9].
Depression is the second leading cause of disability in young to
middle aged adults in low and middle income countries, surpassed
only by HIV/AIDS [10]. Despite this high burden and increasing
global health care strain, limited infrastructure exists to confront
these issues. In Kenya, approximately 0.1% of the national health
care budget is directed toward mental health care [11]. Generally,
there is underdiagnosis of psychiatric illnesses among patients
attending medical facilities in Kenya. This calls for increased
awareness among health care workers, as well as the use of
screening tools that are quick and easy to use in busy clinical
settings [12]. This study seeks to identify the comorbidity of
depression in a rural population of patients receiving care within a
public sector hospital. The Webuye diabetes clinic is located in
Bungoma County, western Kenya. Webuye includes both rural and
semi-urban areas, with a population of around 230,252 people. It
is approximately 380 km west of the capital city, Nairobi. The
diabetes clinic is afﬁliated with Academic Model Providing Access
to Healthcare (AMPATH), and serves over 650 patients [13].
AMPATH, a partnership between Indiana University School of
Medicine, Moi University School of Medicine, and Moi Teaching
and Referral Hospital in Eldoret, Kenya, has developed one of
Africa’s largest and most effective HIV/AIDS prevention and
treatment programs [14]. AMPATH has since expanded into one of
the ﬁrst comprehensive chronic disease management programs
in SSA.
This study was approved by the Kenyan based Moi University
Institutional Research and Ethics Committee and the Institutional
Review Board of the North American investigators.

Table 1
Factors associated with positive depression screen among patients with diabetes
Variable (n)

Depression screen positive n (%)

Gender
Male (113)
17
Female (140)
38
TB history
Positive (6)
1
Negative (243)
52
Aware of HIV status
Yes (89)
19
No (159)
34
If aware, positive HIV result
Yes (4)
1
No (79)
18
Hypertension
Yes (84)
17
No (157)
35
Smoking history
Yes (7)
0
No (242)
53
Chew tobacco, miraa, or khat
Yes (3)
0
No (138)
28
Alcohol use
Yes (26)
4
No (223)
49
Family history of DM
Yes (84)
17
No (164)
36
Has a caretaker
Yes (164)
36
No (78)
15
Food insecure
Yes (83)
23
No (166)
30
Loss to follow up (>12 months)
Yes (22)
15
No (231)
185
Travel time to clinic (>30 min)
Yes (48)
32
No (191)
152

p
0.023*

(15.0)
(27.1)
0.623
(16.7)
(21.4)
0.565
(21.4)
(21.4)
0.654
(25.0)
(22.8)
0.422
(20.2)
(22.3)
0.183
(0.0)
(21.9)
1.000
(0.0)
(20.3)
0.311
(15.4)
(22.0)
0.445
(20.2)
(22.0)
0.380
(22.0)
(19.2)
0.058
(27.7)
(18.1)
0.269
(68.2)
(80.1)
0.601
(66.7)
(79.6)

*p < 0.05 statistically signiﬁcant.

Methods

Results

This study describes prevalence of depressive symptoms as
measured by questions from the ultrabrief depression screening
tool, the Patient Health Questionnaire 2 (PHQ-2) [15], and describes
associations between depressive symptoms and adherence to
medications and clinic visits in a cohort of patients with diabetes in
a rural, resource-constrained clinic setting in western Kenya. In this
retrospective chart review, baseline demographic information was
collected including age, age at diabetes diagnosis, gender, substance
use, food security, travel time to the clinic, income, presence of
comorbid diseases including HIV, tuberculosis, or hypertension, and
family history of diabetes or cardiovascular disease. Responses to
two questions from the PHQ-2, “During the last month have you
been feeling down, depressed or hopeless?” and “During the last
month have you often been bothered by having little interest or
pleasure in doing things?” were recorded. Patients were considered
to screen positive for depression if they answered ‘yes’ to either
question. Longitudinal diabetes management data were also
collected, including current diabetes medication regimen and most
recent HbA1c.
Wilcoxon rank-sum and ManneWhitney tests were used for
statistical analysis of non-parametric data, and Fisher’s exact test
was used for dichotomous data. A p-value of <0.05 was accepted as
statistically signiﬁcant. These tests were used to identify clinical
and demographic differences between patients with and without a
positive screen for depressive symptoms.

Data from 253 patients were collected, of which 55% were female. Mean age was 57.6 years (depression screen-positive 58.1
years, depression screen-negative 55.8 years, p ¼ 0.303) with a
mean age of 50.9 at diabetes diagnosis (depression screen-positive
50.9 years, depression screen-negative 47.9 years; p ¼ 0.160).
Overall, 20.9% screened positive for depression (Table 1), with a
statistically signiﬁcant difference between the proportion of women
(27%) and men (15%) screening positive (p ¼ 0.023). There were no
signiﬁcant differences between those with and without depressive
symptoms with respect to HIV status, presence of tuberculosis, comorbid hypertension, family history of cardiovascular disease or
diabetes, alcohol use, or current diabetes medications.
Regarding diabetes management, 13.2% of patients who screened
positive for depression were lost to follow-up at 12 months following
initial survey, as compared with 7.5% of patients who screened
negative and 8.7% of all diabetes clinic patients (p ¼ 0.269). Signiﬁcant
differences in HbA1c between the two groups were not detected until
24 months following initial survey; however, there was a consistent
trend toward higher Hba1cs amongst patients screening positive for
depression as demonstrated in Fig. 1. Baseline HbA1c for depression
screen-negative patients was 9.9 compared to 10.2 for those
screening positive. After 24 months, patients who obtained regular
HbA1cs demonstrated a signiﬁcant difference, as patients without
depressive symptoms at baseline (N ¼ 29) averaged an HbA1c of 7.5
and those who screened positive (N ¼ 9) averaged 9.5 (p < 0.05).
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Figure 1. HbA1c Trends between depression screen positive and depression screen negative patients with diabetes.

Discussion
These ﬁndings suggest that depressive symptoms are common
among patients with diabetes in rural western Kenya. In North
American and European populations, comorbid depression has
consistently been found to impact diabetes adherence, severity,
and outcomes, and depression treatment interventions among
patients with diabetes improve medication adherence and diabetes outcomes [16]. A higher proportion of women were screen
positive for depression compared to men and this is thought to be
due in part to a reporting bias as male patients tended to be more
reluctant to report symptoms consistent with depression. The
validity of this ﬁnding of a statistically signiﬁcant difference between men and women needs to be further evaluated before
conclusive ﬁndings are reported on this gender disparity. Though
unable to demonstrate signiﬁcant differences in diabetes severity
as indicated by most recent HbA1c, our ﬁndings suggest that those
with depressive symptoms trend toward a higher mean HbA1c
and more loss to follow up than do those without depressive
symptoms.
This study has several limitations. Firstly, the retrospective nature and small sample size limits the power to detect true associations with HbA1c or loss to follow up amongst patients with and
without depressive symptoms. Further, the PHQ-2 has not been
widely validated in SSA populations and may therefore not be a
precise indicator of whether individuals screening positive would
meet diagnostic criteria for major depressive disorder. However,
these questions are quick, easy to implement in busy clinic settings,
and positive response to one or both questions indicates distress
that likely impacts individuals’ diabetes disease severity and ability
to engage in treatment.

Further research is needed to investigate prevalence of depression and relationships between depression, adherence to medication and clinic visits, and outcomes in this population. Larger
studies of depression among people with diabetes and other
chronic diseases in SSA are indicated to better understand relationships between these comorbid illnesses, as well as the
growing discrepancy between the burden of these conditions and
the infrastructure in place to treat them. As chronic disease management programs are rolled out in western Kenya and other
resource-constrained settings, it is important to identify and
address depression and other mental illnesses, not only as signiﬁcant sources of distress and disability in their own right, but as
potential barriers to adherence so that treatment interventions may
be implemented efﬁciently and effectively.
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